US EditionPublished • loading... • Updated
Erleada Shows Survival Advantage in Real-World Study of Metastatic Prostate Cancer
Summary by curetoday.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Real-world head-to-head analysis shows 51% reduction in risk of death for patients with Metastatic castration-sensitive prostate Cancer treated with ERLEADA® (apalutamide) versus Darolutamide without Docetaxel through 24 months - Life Sciences British Col
Johnson & Johnson reported that patients with mCSPC starting ERLEADA without docetaxel had a 51% lower risk of death.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
